SCOPUS 정보 검색 플랫폼

Nature Reviews Drug Discovery

Volumn 7, Issue 7, 2008, Pages 555-556

Novel agents in cystic fibrosis

(2) Storey, Shane a Wald, Graeme a

a Wilson HTM Investment Group (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; AZTREONAM; DENUFOSOL; DORNASE ALFA; DURAMYCIN; MANNITOL; P 680; PTC 124; SODIUM CHANNEL BLOCKING AGENT; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; VX 770; VX 809;

ANTIMICROBIAL ACTIVITY; ARTICLE; CLINICAL TRIAL; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; GENE MUTATION; HUMAN; LUNG FIBROSIS; PRIORITY JOURNAL;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DEOXYCYTOSINE NUCLEOTIDES; GENE THERAPY; HUMANS; MANNITOL; NATRIURETIC AGENTS; OSMOLAR CONCENTRATION; URIDINE;

EID: 46449115311 PISSN: 14741776 EISSN: 14741784 Source Type: Journal
DOI: 10.1038/nrd2603 Document Type: Article

Times cited : (18)

References (10)

1
- 30944452609
- Restoring airway surface-liquid in cystic fibrosis
- Ratjen, F. Restoring airway surface-liquid in cystic fibrosis. N. Engl. J. Med. 354, 291-293 (2006).
- (2006) N. Engl. J. Med , vol.354 , pp. 291-293
- Ratjen, F.¹

2
- 0028129568
- Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis
- Fuchs, H. J. et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N. Engl. J. Med. 331, 637-642 (1994).
- (1994) N. Engl. J. Med , vol.331 , pp. 637-642
- Fuchs, H.J.¹

3
- 37349117582
- Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers
- Glover, W. et al. Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. Int J. Pharm. 349 314-322 (2008).
- (2008) Int J. Pharm , vol.349 , pp. 314-322
- Glover, W.¹

4
- 46449094006
- Press release 04 April 2008
- online
- Pharmaxis. Press release 04 April 2008. Pharmaxis web site [online], (2008).
- (2008) Pharmaxis web site

5
- 46449104428
- Inspire Pharmaceuticals. Press release 06 June. 2008. Inspire Pharmaceuticals web site [online], (2008).
- Inspire Pharmaceuticals. Press release 06 June. 2008. Inspire Pharmaceuticals web site [online], (2008).

6
- 34248597371
- Inhalation of Moli 1901 in patients with cystic fibrosis
- Grasemann, H. et al. Inhalation of Moli 1901 in patients with cystic fibrosis. Chest 131, 1461-1466 (2007).
- (2007) Chest , vol.131 , pp. 1461-1466
- Grasemann, H.¹

7
- 46449095216
- Press release 06 March 2007
- online
- Lantibio. Press release 06 March 2007. Lantibio web site [online], (2007).
- (2007) Lantibio web site

8
- 41149164824
- Pharmacological properties of N′- 4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease
- Hirsh, A. J. et al. Pharmacological properties of N′- 4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J. Pharmacol. Exp. Ther. 325, 77-88 (2008).
- (2008) J. Pharmacol. Exp. Ther , vol.325 , pp. 77-88
- Hirsh, A.J.¹

9
- 46449111805
- Press release 05 October 2007
- PTC Therapeutics, online
- PTC Therapeutics. Press release 05 October 2007. PTC Therapeutics web site [online], (2007).
- (2007) PTC Therapeutics web site

10
- 46449088507
- Vertex Pharmaceuticals. Press release 05 October 2007. Vertex Pharmaceuticals web site [online],
- Vertex Pharmaceuticals. Press release 05 October 2007. Vertex Pharmaceuticals web site [online],

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.